home / stock / mcrb / mcrb articles
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Seres Therapeutics Inc (NASDAQ: MCRB) received FDA Fast Track Designation for SER-155, an investigational oral, cultivated microbiome therapeu...
U.S. stocks traded lower this morning, with the Dow Jones falling more than 200 points on Tuesday. Following the market opening Tuesday, the Dow tr...
Gainers Benson Hill, Inc. (NYSE: BHIL) shares jumped 48.1% to $0.3740. Seres Therapeutics, Inc. (NASDAQ: MCRB) climbed 45.9% to $1.20. Seres Ther...
U.S. stocks traded higher this morning, following the release of jobs report for October. Following the market opening Friday, the Dow traded up 0....
Gainers OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that its merger with Syntec was approved by shareholder...
STAMFORD, Conn., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating Seres Therapeutics, Inc. (NASDAQ:MCRB) ("Seres" or the "C...
News, Short Squeeze, Breakout and More Instantly...
Seres Therapeutics Inc. Company Name:
MCRB Stock Symbol:
NASDAQ Market:
Seres Therapeutics Inc. Website:
Clinical data readout expected end of Q3 2024 SER-155 and other Seres microbiome therapeutic candidates have potential to expand microbiome therapeutic franchise into additional medically vulnerable patient populations Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiom...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
VOWST net sales of $10.4 million for the fourth quarter of 2023 and $19.6 million since launch in June through year-end 2023 Significant adoption of VOWST since launch in June 2023 through year-end 2023 with 2,833 patient enrollment forms received and 2,015 new patient starts ...